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Sir,
Meropenem and imipenem are carbapenems that remain active
against organisms carrying most Ambler classes A and C b-
lactamases which include many Gram-negative bacilli, including
Acinetobacter spp. However, carbapenem resistance is increasingly
encountered in Acinetobacter isolates worldwide.1 Mechanisms of
carbapenem resistance include the loss of porins, increase in efflux
activity and the production of Ambler class Bmetallo-b-lactamases
such as VIM and IMP enzymes. Another mechanism is the
production of Ambler class D oxacillinases (OXA enzymes) with
carbapenem-hydrolysing activity, such as OXA-23 and OXA-51
carbapenemases. A multidrug-resistant OXA-23 carbapenemase-
producing Acinetobacter baumannii clone has spread rapidly
among UK hospitals in recent years.2 We report two Acinetobacter
isolates producing OXA-23 enzyme in the Irish Republic.
Two meropenem-resistant Acinetobacter isolates were encoun-
tered in our hospital in 2005. The first isolate (05/29540) was
isolated from a biliary drain fluid specimen of a 62-year-old
patient who underwent a laparotomy for gall bladder perforation
and associated intra-abdominal sepsis. She had underlying pan-
creatic carcinoma and diabetes mellitus. Recent antimicrobial
therapy included piperacillin/tazobactam, ciprofloxacin and
vancomycin. The patient did not receive a carbapenem prior to
the isolation of the organism. The second isolate (05/12659) was
cultured from a sputum specimen of a 49-year-old patient with a
history of complicated inflammatory bowel disease associated
with recent intensive care (ICU) admission for intra-abdominal
sepsis and methicillin-resistant Staphylococcus aureus vascular
catheter-related bloodstream infection. Recent antimicrobial
treatment included meropenem, ciprofloxacin, vancomycin and
caspofungin. He was also on immunosuppressants, methotrexate
and infliximab, and was neutropenic (neutrophil count of <0.1 ·
109/L) at the time of the organism’s isolation. The two cases were
epidemiologically unrelated in time or space.
Both isolates were presumptively identified as A. baumannii
using the Vitek-2 automated identification and susceptibility test
system (bioMerieux, Basingstoke, UK), but amplified ribosomal
DNA restriction analysis (ARDRA) subsequently confirmed both
isolates to be Acinetobacter genomic species 3. Both isolates
demonstrated resistance to b-lactams including meropenem (MIC
 16 mg/L) and to quinolones. 05/29540 was also resistant to
gentamicin and co-trimoxazole but susceptible to tobramycin and
amikacin. 05/12659 was susceptible to gentamicin, tobramycin,
amikacin and co-trimoxazole. Antimicrobial susceptibility results
with agar dilution and Etest (AB Biodisk, Solna, Sweden)
methods using CLSI guidelines are shown in Table 1.
Using Etest metallo-b-lactamase (MBL) strips (imipenem
MIC: imipenem + EDTA MIC) (AB Biodisk), ratios of 24 and
12 were obtained for 05/29540 and 05/12659, respectively,
suggesting the presence of MBL activity. However, PCR using
VIM and IMP primers did not reveal the presence of relevant
amplicons on agarose gel electrophoresis. Isoelectric focusing
revealed a b-lactamase with a pI value of 6.7 for both isolates as
well as the OXA-23 positive control, suggesting the presence of
OXA-23 carbapenemase activity. PCR using OXA-23-like
primers revealed a single amplicon in the region between 800
and 900 bp in size for both isolates and the OXA-23 positive
control.3 Nucleotide sequencing of the amplicons demonstrated
>99.5% and 100% homology with the blaOXA-23 carbapenemase
gene (GenBank database accession number AJ132105), from bp
24 to bp 822 for 05/29540 and from bp 31 to bp 822 for
05/12659.3 Nucleotide sequences in the regions of variation
between blaOXA-23, blaOXA-27 and blaOXA-49 are all consistent
with blaOXA-23 for both isolates. PCR with OXA-51-like primers
did not reveal the presence of a blaOXA-51-like carbapenemase
gene in either isolate,4 while amplicons of the expected size
were obtained with the positive control as well as the
A. baumannii ATCC 19606 strain. PCR also did not detect the
presence of class 1 integrons in both isolates.2 DNA macro-
restriction followed by PFGE revealed the two isolates’ profiles
to be distinct from one another, suggesting that they are not
clonally related.
OXA carbapenemases are increasingly encountered world-
wide, especially in the nosocomial setting. To our knowledge,
these are the first reported isolates of OXA-23 carbapenemases
in Acinetobacter spp. in the Irish Republic. They were associated
with risk factors for antimicrobial resistance such as prior
antibiotic treatment, ICU admission, immunosuppression and
severe underlying diseases. Acinetobacter genomic species 3,
like A. baumannii, has been associated with nosocomial cross-
infection and is the predominant Acinetobacter sp. in some
institutions.5 In view of their roles in nosocomial outbreaks,
accurate speciation of Acinetobacter spp. is essential. Thus we
would like to highlight the problem of misidentification of
Acinetobacter spp. by commercial systems utilizing phenotypic
tests (e.g.Vitek-2) and the need for further molecular typing for
accurate speciation.
Interestingly, both isolates met the screening criterion
(imipenem to imipenem/EDTA ratio of 8) for MBL activity
using the Etest MBL strips, even though subsequent PCR assays
did not indicate the presence of blaVIM or blaIMP genes. Such a
phenomenon has also been observed by Segal et al.6 However, the
imipenem to imipenem/EDTA ratios of 05/29540 and 05/12659
were lower (8 and 4, respectively) with the agar dilution method,
thus suggesting that the latter method may be more specific
for the detection of MBL activity. Therefore, Etest for the
detection of MBL in Acinetobacter spp. must be used with caution
and requires further validation before a positive result is
conclusive.
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The presence of OXA-23 carbapenemase-producing
Acinetobacter spp. in the Irish Republic has not yet been
associated with outbreak problems as seen in the UK. Never-
theless, the emergence of such a resistance mechanism in
Acinetobacter isolates represents a worrying trend, although it
is probably unsurprising given the recent trends in carbapenem
resistance elsewhere in the world. We would like to reiterate
the importance of prudence in antimicrobial prescription and
adherence to infection control measures in the efforts to control the
rise of such resistance mechanisms, as well as the urgent need for
new antimicrobial agents in the face of pan-b-lactam resistance.
Acknowledgements
We would like to thank Dr Susan Brown for the donation of the
OXA positive controls and Dr Jane Turton for performing the
ARDRA and PFGE on our isolates.
Transparency declarations
We have no affiliations with the pharmaceutical industry or any
related commercial concerns.
References
1. Afzal-Shah M, Livermore DM. Worldwide emergence of
carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother
1998; 41: 576–7.
2. Turton JF, Kaufmann ME, Glover J et al. Detection and typing of
integrons in epidemic strains of Acinetobacter baumannii found in the
United Kingdom. J Clin Microbiol 2005; 43: 3074–82.
3. Donald HM, Scaife W, Amyes SGB et al. Sequence analysis of
ARI-1, a novel OXA b-lactamase, responsible for imipenem resistance
in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother 2000;
44: 196–9.
4. Turton JF, Ward ME, Woodford N et al. The role of ISAba1 in
expression of OXA carbapenemase genes in Acinetobacter baumannii.
FEMS Microbiol Lett 2006; 258: 72–7.
5. Traub WH, Bauer D. Surveillance of nosocomial cross-infections
due to three Acinetobacter genospecies (Acinetobacter baumannii,
genospecies 3 and genospecies 13) during a 10-year observation period:
serotyping, macrorestriction analysis of genomic DNA and antibiotic
susceptibilities. Chemotherapy 2000; 46: 282–92.
6. Segal H, Elisha BG. Use of Etest MBL strips for the detection of
carbapenemases in Acinetobacter baumannii. J Antimicrob Chemother
2005; 56: 598.
Journal of Antimicrobial Chemotherapy
doi:10.1093/jac/dkl359
Advance Access publication 2 September 2006
Antibiotic susceptibility of 50 clinical isolates of
Burkholderia pseudomallei from Singapore
Suppiah Paramalingam Sivalingam*, Siew Hoon Sim,
Lay Tin Aw and Eng Eong Ooi
Defence Medical & Environmental Research Institute, DSO
National Laboratories, 27 Medical Drive, 117510, Singapore
Keywords: MICs, melioidosis, prophylaxis, Etest
*Corresponding author. Tel: +65-6485-7255; Fax: +65-648-7262;
E-mail: ssuppiah@dso.org.sg
Sir,
Burkholderia pseudomallei is the aetiological agent of melioi-
dosis, a potentially fatal disease in humans and animals. In
Singapore, a high incidence of melioidosis cases was observed in
early 2004 with a high mortality rate (40%).1 Prevention of
exposure is difficult as this organism is common in the soil of
many parts of south-east Asia. In the absence of a vaccine,
antibiotic prophylaxis for those predisposed to melioidosis could
be explored. Others have shown that oral doxycycline/
ciprofloxacin could prevent melioidosis in experimentally
infected mice.2 We thus examined the in vitro susceptibility
of 50 clinical isolates obtained from five local hospitals in
Singapore, between the years 1996 and 2004, of which 31 were
from the outbreak in 2004,1 to four oral antibiotics, namely
amoxicillin/clavulanic acid, doxycycline, ciprofloxacin and
co-trimoxazole.
MICs were determined by the Etest (AB Biodisk, Solna,
Sweden) method using Mueller–Hinton (MHII) agar (Oxoid,
Basingstoke, UK) and the plates were read after incubation at
37C for 24 h. The MIC of each antibiotic (in mg/L) for each
B. pseudomallei isolate was reported as susceptible, intermediate
or resistant as per CLSI3 guidelines: 8/4, 16/8 and 32/16
for amoxicillin/clavulanic acid, 4, 8 and 16 for doxycycline,
2/38, – and 4/76 for co-trimoxazole and 1, 2 and 4 for
ciprofloxacin. E. coli ATCC 25922 and Pseudomonas aeruginosa
Table 1. Antimicrobial susceptibility patterns of the
Acinetobacter isolates
Antibiotic 05/29540 05/12659
MICs (mg/L) using the agar dilution method
Ampicillin >128 >128
Piperacillin >128 >128
Amoxicillin/clavulanate >128 >128
Piperacillin/tazobactam 128 128
Cefoxitin 128 >128
Cefotaxime 64 32
Ceftazidime 32 16
Meropenem 64 128
Meropenem + EDTA (320 mg/L) 8 32
Imipenem 128 128
Imipenem + EDTA (320 mg/L) 16 32
Nalidixic acid >128 >128
Ciprofloxacin 8 4
Gentamicin 32 1
Amikacin 0.5 2
MICs (mg/L) using the Etest method
Meropenem 32 32
Imipenem (MBL test) 24 12
Imipenem + EDTA (MBL test) 1 1
Tigecycline 0.25 0.25
Colistin 0.25 0.5
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